BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Hereditary angioedema clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for hereditary angioedema: 25 (12 sponsors; 1 newly posted in the last 180 days, 1 stopped in the last 180 days; 1 new-entrant sponsors). Momentum score 26, rank 11 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 0, Phase 2 5, Phase 3 13, Phase 4 1, N/A 6.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Pharvaris Netherlands B.V. PHVS3P3 300
ADARx Pharmaceuticals, Inc. ADRX3P3 2, P2 100
Astria Therapeutics, Inc.3P3 2, P2 101
BioCryst Pharmaceuticals BCRX2P3 200
Ionis Pharmaceuticals, Inc. IONS2P3 201
Intellia Therapeutics NTLA3P2 1, NA 1, P3 100
Octapharma1P3 101
Takeda TAK4NA 401
BioMarin Pharmaceutical BMRN1P2 100
CSL Behring1NA 100
KalVista Pharmaceuticals, Ltd. new entrant1P4 110
Shanghai Argo Biopharmaceutical Co., Ltd.1P2 100

New-entrant sponsors: KalVista Pharmaceuticals, Ltd..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3Ionis Pharmaceuticals, Inc. IONSNCT05392114 A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)Hereditary Angioedemaactive not recruiting154
2026-12 est.P3Astria Therapeutics, Inc.NCT06842823 A Study of Navenibart in Participants With Hereditary AngioedemaHereditary Angioedema (HAE)active not recruiting157

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-07-21P3Pharvaris Netherlands B.V. PHVSNCT06669754 Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEHereditary Angioedema (HAE)completed85
2026-06-30 est.P2Shanghai Argo Biopharmaceutical Co., Ltd.NCT06846398 A Phase 2 in Adult Subjects With Hereditary AngioedemaHereditary Angioedema (HAE)active not recruiting25
2026-05-27P3KalVista Pharmaceuticals, Ltd.NCT05511922 PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 TrialHereditary Angioedemacompleted11
2026-05-27P3KalVista Pharmaceuticals, Ltd.NCT05505916 An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult PaHereditary Angioedemacompleted145

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "hereditary angioedema"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.